About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Provigil Patent Extension Accorded To Cephalon

by Medindia Content Team on March 31, 2006 at 6:00 PM
Font : A-A+

Provigil Patent Extension Accorded To Cephalon

Cephalon has been accorded a further six months of patent extension by the FDA for its pediatric sleep disorder treatment medication, Provigil.

Cephlaon had complied with the terms of an explicit written request that entailed the provision of clinical studies data after studying the effects of provigil on pediatric patients.

Advertisement

Cephalon has settled the 'provogil'patent infringement litigation with four generic firms, and under this settlement, each of the four defendants will have a non-exclusive royalty bearing right to market and sell a generic version of Provigil in the US, due to become effective in April 2012.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Fermented Skin Care
Television Binge-Watching May Boost the Risk of Deadly Blood Clots
Western Diet may Augment the Risk of Autoimmune Diseases
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)